Voie d'immunisation et séquence d'administration de l ... - TEL

tel-00827710, version 1 - 29 May 2013
immune cells, reducing the immunosuppressive action of regulatory T cells and MDSCs.
Farsaci et al. tested combinations of sunitinib with a vaccine in a mouse tumor model (Farsaci
et al., 2012). Co-administration of sunitinib with vaccine, or sequential injection of vaccine
and then sunitinib did not show an anti-tumor benefit compared to sunitinib alone. In contrast,
when vaccine was administered after sunitinib treatment, it induced a better anti-tumor
response. The possible explanation is that sunitinib triggered a less immunosuppressive
environment, favoring the development of a more robust immune response once vaccine was
administered.
(iii) Determine optimal sequence and timing to combine
several treatments
From our knowledge regarding mechanism, processing and interactions between the different
molecules, we would eventually be able to predict what may be the optimal timing and
treatment strategy for their administration and combination (Figure 57). Although, for this, a
much more thorough understanding of their multiple actions on tumors and on the immune
system is absolutely necessary. Once established and confirmed by experimental model data,
these predictions would then have to be tested in pre-clinical trials.
Page 175 of 256